The present study is a prospective follow-up study, and by analyzing the results of 43 patients with moderate-to-severe asthma after 4 and 16 weeks of treatment, we preliminarily demonstrated that the clinical efficacy of omalizumab for moderate-to-severe asthma may be able to be assessed based on the serum 4-week IgE/baseline IgE ratio and tryptase, which may help in early (up to 16 weeks or even at 4 weeks) clinical decision-making about whether to continue omalizumab. The gene discussed is IGHE; the disease is asthma.